Abstract:Background: The BRAF mutation V600E (BRAF(V600E)) is the most common genetic alteration in papillary thyroid carcinoma (PTC), while overexpression of X-linked inhibitor of apoptosis (XIAP) has been found in various tumors. Both of these events are implicated in carcinogenesis, tumor progression, recurrence, etc. There are few reports, however, of the BRAF V600E mutation and XIAP overexpression in PTC patients. The aim of this study was to investigate the frequency of the BRAF V600E mutation in PTC and its relationship to clinicopathological parameters and the expression of XIAP.Methods: Genomic DNA was extracted from 123 paraffin-embedded PTC tumor tissue samples and amplified for analysis of the V600E mutation in exon 15 of the BRAF gene by polymerase chain reaction. XIAP expression was examined by immunohistochemical methods in 46 PTCs, 18 benign nodular goiters, and 10 Hashimoto's thyroiditis samples.Results: The BRAF V600E mutation was found in 34.1% of PTC, and was especially prevalent in the classic type. BRAF V600E was significantly correlated with younger age at diagnosis (p=0.026), tumor size (p=0.009), and histological variants (p=0.024). There was a trend towards association with extrathyroidal invasion (p=0.067). By logistic regression analysis, a significant relationship was found between tumor size and the BRAF V600E mutation (p=0.03). XIAP was expressed in 82.6% of PTCs, which was a higher percentage than observed in the group of benign thyroid disorders (35.7%, p<0.001). Neither the intensity (p=0.611) nor the extent (p=0.723) of XIAP staining was correlated with the presence of BRAF V600E in PTC patients.Conclusions: These data indicate that BRAF V600E is associated some of the aggressive clinicopathological features of PTC including younger age at diagnosis, larger tumor size, and classic histological type, as well as also extrathyroidal invasion. XIAP-positive staining was more prevalent in PTCs than in the benign thyroid disorders. Although BRAF V600E and XIAP expression are commonly seen in PTC, their presence together seems unrelated.

BRAF Mutation in Papillary Thyroid Carcinoma (PTC) and Its Association with Clinicopathological Features and Systemic Inflammation Response Index (SIRI).

Risk Factors for Neck Nodal Metastasis in Papillary Thyroid Cancer with BRAF V600E Mutation.

Associations of the BRAF V600E Mutation with Sonographic Features in Patients with Papillary Thyroid Carcinoma

Risk and Prognostic Factors for BRAFV600E Mutations in Papillary Thyroid Carcinoma

BRAFV600E mutation and NIS expression in papillary thyroid carcinomas

Clinical Significance of BRAF Mutation and Expression in Papillary Thyroid Carcinoma

The association between BRAF V600E mutation and pathological features in PTC

Conventional Ultrasound, Immunohistochemical Factors and BRAFV600E Mutation in Predicting Central Cervical Lymph Node Metastasis of Papillary Thyroid Carcinoma.

Brafv600e Mutation in Papillary Thyroid Microcarcinoma: A Meta-Analysis

Poorer Prognosis and Higher Prevalence of BRAFV600E Mutation in Synchronous Bilateral Papillary Thyroid Carcinoma

Association Between BRAF V600E Mutation and Ultrasound Features in Papillary Thyroid Carcinoma Patients with and Without Hashimoto's Thyroiditis.

Association of BRAF(V600E) Mutation with Ultrasonographic Features and Clinicopathologic Characteristics of Papillary Thyroid Microcarcinoma: A Retrospective Study of 116 Cases

The Clinicopathological Features of BRAF Mutated Papillary Thyroid Cancers in Chinese Patients

Association Between BRAF and RAS Mutations, and RET Rearrangements and the Clinical Features of Papillary Thyroid Cancer.

The Prognostic Implication of the BRAF V600E Mutation in Papillary Thyroid Cancer in a Chinese Population

Braf(V600e) Mutation and X-Linked Inhibitor of Apoptosis Expression in Papillary Thyroid Carcinoma

Detection of BRAF Mutation and Its Clinical Significance in Thyroid Cancer

Ultrasound Features Suspicious For Malignancy Predict The Risk Of Braf Mutation In Papillary Thyroid Carcinoma

BRAF V600E Mutation and Its Association with Clinicopathological Features of Papillary Thyroid Microcarcinoma: A Meta-Analysis

Association of the T1799A BRAF Mutation with Tumor Extrathyroidal Invasion, Higher Peripheral Platelet Counts, and Over-Expression of Platelet-Derived Growth Factor-B in Papillary Thyroid Cancer

Relationship Between BRAF V600E Gene Mutation and the Clinical and Pathologic Characteristics of Papillary Thyroid Microcarcinoma.